Brokerages Set BioNTech SE Sponsored ADR (NASDAQ:BNTX) Target Price at $129.12

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has been given a consensus recommendation of “Moderate Buy” by the nineteen analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $129.1250.

A number of research firms have recently weighed in on BNTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research note on Monday, July 6th. Wall Street Zen upgraded shares of BioNTech from a “sell” rating to a “hold” rating in a research report on Saturday, July 18th. Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a report on Monday, June 1st. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of BioNTech in a research report on Friday, June 5th. Finally, Canaccord Genuity Group reduced their price objective on BioNTech from $171.00 to $158.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th.

BioNTech Price Performance

Shares of NASDAQ BNTX opened at $89.33 on Monday. BioNTech has a 52 week low of $79.52 and a 52 week high of $124.00. The business’s 50 day moving average price is $91.29 and its 200 day moving average price is $97.68. The company has a quick ratio of 8.74, a current ratio of 8.80 and a debt-to-equity ratio of 0.01. The firm has a market cap of $22.59 billion, a P/E ratio of -15.19 and a beta of 1.32.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, May 4th. The company reported ($2.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.52) by $0.26. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.30%. The company had revenue of $136.71 million during the quarter, compared to analyst estimates of $207.42 million. During the same period last year, the firm posted ($1.73) EPS. BioNTech’s revenue for the quarter was down 35.4% compared to the same quarter last year. On average, sell-side analysts expect that BioNTech will post -5.79 earnings per share for the current year.

BioNTech announced that its Board of Directors has approved a share repurchase program on Thursday, May 7th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 4.2% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s leadership believes its shares are undervalued.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada boosted its position in BioNTech by 95.9% in the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock worth $653,000 after purchasing an additional 3,514 shares in the last quarter. NewEdge Advisors LLC purchased a new position in shares of BioNTech during the 1st quarter valued at approximately $167,000. Russell Investments Group Ltd. lifted its stake in shares of BioNTech by 368,800.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,067 shares of the company’s stock valued at $1,178,000 after purchasing an additional 11,064 shares during the period. Natixis acquired a new position in shares of BioNTech in the 2nd quarter valued at $985,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in BioNTech by 2.9% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 492,045 shares of the company’s stock worth $52,416,000 after buying an additional 13,788 shares in the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.